Therapeutic switching of metronidazole anti-cancerous compounds as anti SARS-COV-2 inhibitors: integration of QSAR, molecular docking, MD simulation and ADMET analysis
Discover Life · 2024
DOI: 10.1007/s11084-024-09653-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Life, 2024. Verfasst von Shagufta Parveen und 9 weiteren Autor:innen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The global economy and public health are seriously at risk because of the COVID-19 outbreak brought on by the SARS-CoV-2. Currently, there is no specific medication available to treat COVID-19 patients. A quick method used to find out the treatment of newly developing infectious diseases like SARS COV-2 by drug repurposing. Metronidazole (3-methyl-5-nitroimidazole) is a synthetic, azomycin derivative having strong bacteriocidal and antiparasitic properties. Metronidazole (MTZ) derivatives are commercially broad spectrum containing pertinent antibacterial activity and a reasonable safety profile. MTZ structures were designed using chemdraw professional and subjected to field base and atom base QSAR and displayed good results by identifying 9 compounds as active. Molecular docking was performed with 9 proteins from which highest docking score was ranged from − 6.305 to − 8.044 of MT35 with 7aot as compared to standard drug (Lopinavir, showed docking score − 5.504 with same protein). Docking was further validated by redocking by RMSD score in range of 2 Å. MMGB/SA results showed the negative binding energy values of docked protein–ligand complexes comparable to standard drug and MD stimulation were also performed for the structure flexibility showed 1.00 Å RMSF for three protein at maximum fluctuation. Selected drug (MT35) showed good ADME properties which may need to be synthesized followed by in vitro and in vivo study against SARS-CoV-2. Graphical Abstract
Zitieren
APA
Parveen, S., Khalil, R., Shafiq, N., Rashid, M., Nazli, Z., Dawoud, T. M., Metouekel, A., Bourhia, M., younous, Y. A., & Moveed, A. (2024). Therapeutic switching of metronidazole anti-cancerous compounds as anti SARS-COV-2 inhibitors: integration of QSAR, molecular docking, MD simulation and ADMET analysis. Discover Life. https://doi.org/10.1007/s11084-024-09653-6
Vancouver
Parveen S, Khalil R, Shafiq N, Rashid M, Nazli Z, Dawoud TM, et al. Therapeutic switching of metronidazole anti-cancerous compounds as anti SARS-COV-2 inhibitors: integration of QSAR, molecular docking, MD simulation and ADMET analysis. Discover Life. 2024. doi:10.1007/s11084-024-09653-6
BibTeX
@article{Parveen2024,
author = {Parveen, Shagufta and Khalil, Rabia and Shafiq, Nusrat and Rashid, Maryam and Nazli, Zill-i-Huma and Dawoud, Turki M. and Metouekel, Amira and Bourhia, Mohammed and younous, Youssouf Ali and Moveed, Aniqa},
title = {Therapeutic switching of metronidazole anti-cancerous compounds as anti SARS-COV-2 inhibitors: integration of QSAR, molecular docking, MD simulation and ADMET analysis},
journal = {Discover Life},
year = {2024},
doi = {10.1007/s11084-024-09653-6}
}
EUVIMED